Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative Pregabalin for PONV in Laparoscopic Surgery
NCT05529004Phase 2
Key facts
- Status
- Unknown
- Start
- Sep 2022
- Primary completion
- Oct 2022
- Sponsor
- Al-Safwa University College
- Modality
- Small Molecules
- Drugs
- pregabalin
- Conditions
- postoperative nausea and vomiting (PONV)
01
Overview
Phase 2, randomised, double-blind trial in postoperative nausea and vomiting (PONV) comparing Pregabalin with Placebo (2 arms). Primary endpoint: Preoperative Pregabalin to Prevent Postoperative Nausea & Vomiting in Laparoscopic Surgery. Status: unknown.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Pregabalin
Pregabalin 75mg orally 30 min before surgery
Placebo
Placebo orally 30 min before surgery
03
Who it enrols
Adult patients (18-55 years) with ASA physical status 1 undergoing elective laparoscopic cholecystectomy under general anesthesia. Excludes patients >55 years, emergency operations, pregnant patients, those with cardiac, respiratory, or endocrine diseases, and those receiving total intravenous anesthesia.
04
Endpoints
Primary
Preoperative Pregabalin to Prevent Postoperative Nausea & Vomiting in Laparoscopic Surgery
Beyond the preview
Go deeper on NCT05529004.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05529004.